On Mar. 16, 2023, Pfizer announced that the U.S. Food and Drug Administrationﾒs Antimicrobial Drugs Advisory Committee voted 16 to 1 that available data supported the safety and effectiveness of PAXLOVIDﾙ (nirmatrelvir tablets and ritonavir tablets) for the treatment of mild-to-moderate COVID-19 in adult patients who are at high risk for progression to severe illness.